EVOLUS, INC. Estimated Litigation Liability, Current
EVOLUS, INC. (EOLS) had Estimated Litigation Liability, Current of $0 as of 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LitigationReserveCurrent · last filed 2025-03-04
- 2024-12-31: Estimated Litigation Liability, Current $0.00.
- 2023-12-31: Estimated Litigation Liability, Current $0.00.
- 2023-09-30: Estimated Litigation Liability, Current $0.00.
- 2023-06-30: Estimated Litigation Liability, Current $0.00.
| Period end | Estimated Litigation Liability, Current |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-04 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-04 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 |
| 2022-12-31 | $5.00M 10-K · filed 2024-03-07 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.00M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $5.00M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $15.00M 10-K · filed 2023-03-08 |
| 2021-09-30 | $15.00M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $30.00M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $30.00M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $63.42M 10-K · filed 2022-03-03 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |